Corcept Therapeutics Inc. $CORT reported strong second-quarter 2026 results, with revenue rising to $256.1 million, up 31.7% from a year earlier and ahead of estimates. Gross profit climbed to $252.1 million, while operating profit increased to $41.3 million, reflecting improved profitability across the business.
Net income attributable to common shareholders came in at $42.1 million, or $0.36 per diluted share, both higher than a year ago. The company also ended the quarter with $111.0 million in cash and cash equivalents, supporting its financial position.
Selected highlights:
Operating cash flow was $33.5 million, and capital spending remained modest. The results were well received by investors, with the stock rising 18.35% since the market close.
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Corcept Therapeutics Inc. Insider Trading Activity
Corcept Therapeutics Inc. insiders have traded $CORT stock on the open market 36 times in the past 6 months. Of those trades, 2 have been purchases and 34 have been sales.
Here’s a breakdown of recent trading of $CORT stock by insiders over the last 6 months:
- ATABAK MOKARI (Chief Financial Officer) has made 0 purchases and 9 sales selling 120,000 shares for an estimated $9,554,181.
- SEAN MADUCK (See Remarks) has made 0 purchases and 7 sales selling 125,000 shares for an estimated $8,882,863.
- WILLIAM GUYER (Chief Development Officer) has made 0 purchases and 8 sales selling 120,000 shares for an estimated $6,667,939.
- JOSEPH K BELANOFF (Chief Executive Officer) has made 0 purchases and 2 sales selling 66,198 shares for an estimated $3,315,685.
- G LEONARD JR BAKER has made 2 purchases buying 100,000 shares for an estimated $3,313,808 and 0 sales.
- JAMES N WILSON has made 0 purchases and 6 sales selling 20,000 shares for an estimated $1,715,034.
- DAVID L MAHONEY sold 20,000 shares for an estimated $1,690,506
- JOSEPH DOUGLAS LYON (See Remarks) sold 5,000 shares for an estimated $325,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Corcept Therapeutics Inc. Hedge Fund Activity
We have seen 189 institutional investors add shares of Corcept Therapeutics Inc. stock to their portfolio, and 194 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FIRST TRUST ADVISORS LP added 1,480,059 shares (+213.5%) to their portfolio in Q1 2026, for an estimated $59,661,178
- TD ASSET MANAGEMENT INC removed 994,844 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $40,102,161
- MPM BIOIMPACT LLC added 985,700 shares (+inf%) to their portfolio in Q1 2026, for an estimated $39,733,567
- UBS GROUP AG added 948,817 shares (+228.7%) to their portfolio in Q1 2026, for an estimated $38,246,813
- TWO SIGMA INVESTMENTS, LP added 917,925 shares (+3283.1%) to their portfolio in Q1 2026, for an estimated $37,001,556
- EPOCH INVESTMENT PARTNERS, INC. removed 816,652 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $32,919,242
- FMR LLC added 775,552 shares (+32.1%) to their portfolio in Q1 2026, for an estimated $31,262,501
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Corcept Therapeutics Inc. Price Targets
Multiple analysts have issued price targets for $CORT recently. We have seen 4 analysts offer price targets for $CORT in the last 6 months, with a median target of $91.5.
Here are some recent targets:
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $95.0 on 05/28/2026
- Edward Nash from Canaccord Genuity set a target price of $135.0 on 05/28/2026
- Ashwani Verma from UBS set a target price of $72.0 on 05/13/2026
- David Amsellem from Piper Sandler set a target price of $88.0 on 05/01/2026
